Search

Your search keyword '"Liu, Dianchang"' showing total 25 results
Start Over Author "Liu, Dianchang" Publication Year Range Last 10 years
25 results on '"Liu, Dianchang"'

1. Genome‐wide meta‐analysis and fine‐mapping prioritize potential causal variants and genes related to leprosy

Author

Wang, Zhenzhen, primary, Liu, Tingting, additional, Li, Wenchao, additional, Yu, Gongqi, additional, Mi, Zihao, additional, Wang, Chuan, additional, Liao, Xiaojie, additional, Huai, Pengcheng, additional, Chu, Tongsheng, additional, Liu, Dianchang, additional, Sun, Lele, additional, Fu, Xi'an, additional, Sun, Yonghu, additional, Wang, Honglei, additional, Wang, Na, additional, Liu, Jianjun, additional, Liu, Hong, additional, and Zhang, Furen, additional

Published
2023
Full Text
View/download PDF

5. Prevalence, risk factors, and medical costs of Chlamydia trachomatis infections in Shandong Province, China: a population-based, cross-sectional study

Author

Huai, Pengcheng, Li, Furong, Li, Zhen, Sun, Lele, Fu, Xi’an, Pan, Qing, Yu, Gongqi, Chai, Zemin, Chu, Tongsheng, Mi, Zihao, Bao, Fangfang, Wang, Honglei, Zhou, Bingni, Wang, Chuan, Sun, Yonghu, Niu, Guiye, Zhang, Yuan, Fu, Fanghui, Lang, Xiaoqiao, Wang, Xiaoling, Zhao, Hui, Liu, Daina, Liu, Hong, Liu, Dianchang, Liu, Jian, Xu, Aiqiang, and Zhang, Furen

Published
2018
Full Text
View/download PDF

9. The role of an active surveillance strategy of targeting household and neighborhood contacts related to leprosy cases released from treatment in a low-endemic area of China

Author

Wang, Na, primary, Chu, Tongsheng, additional, Li, Furong, additional, Wang, Zhenzhen, additional, Liu, Dianchang, additional, Chen, Mingfei, additional, Wang, Honglei, additional, Niu, Guiye, additional, Liu, Dan, additional, Zhang, Mingkai, additional, Xu, Yuanyuan, additional, Zhang, Yan, additional, Li, Jinghui, additional, Li, Zhen, additional, You, Jiabao, additional, Mao, Liguo, additional, Li, Huaizhang, additional, Chen, Yongjin, additional, Liu, Hong, additional, and Zhang, Furen, additional

Published
2020
Full Text
View/download PDF

14. Seroprevalence and associated factors of HSV-2 infection among general population in Shandong Province, China

Author

Huai, Pengcheng, primary, Li, Furong, additional, Li, Zhen, additional, Sun, Lele, additional, Fu, Xi’an, additional, Pan, Qing, additional, Yu, Gongqi, additional, Chai, Zemin, additional, Chu, Tongsheng, additional, Mi, Zihao, additional, Bao, Fangfang, additional, Wang, Honglei, additional, Zhou, Bingni, additional, Wang, Chuan, additional, Sun, Yonghu, additional, Niu, Guiye, additional, Zhang, Yuan, additional, Fu, Fanghui, additional, Lang, Xiaoqiao, additional, Wang, Xiaoling, additional, Zhao, Hui, additional, Liu, Daina, additional, Liu, Hong, additional, Liu, Dianchang, additional, Liu, Jian, additional, Xu, Aiqiang, additional, and Zhang, Furen, additional

Published
2019
Full Text
View/download PDF

16. Prediction of leprosy in the Chinese population based on a weighted genetic risk score

Author

Wang, Na, primary, Wang, Zhenzhen, additional, Wang, Chuan, additional, Fu, Xi'an, additional, Yu, Gongqi, additional, Yue, Zhenhua, additional, Liu, Tingting, additional, Zhang, Huimin, additional, Li, Lulu, additional, Chen, Mingfei, additional, Wang, Honglei, additional, Niu, Guiye, additional, Liu, Dan, additional, Zhang, Mingkai, additional, Xu, Yuanyuan, additional, Zhang, Yan, additional, Li, Jinghui, additional, Li, Zhen, additional, You, Jiabao, additional, Chu, Tongsheng, additional, Li, Furong, additional, Liu, Dianchang, additional, Liu, Hong, additional, and Zhang, Furen, additional

Published
2018
Full Text
View/download PDF

17. Evaluation of ProspectiveHLA-B*13:01Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy

Author

Liu, Hong, Wang, Zhenzhen, Bao, Fangfang, Wang, Chuan, Sun, Lele, Zhang, Huimin, Yu, Gongqi, Mi, Zihao, Li, Jianke, Li, Lulu, Zhao, Qing, Yue, Zhenhua, Zhao, Wei, Yu, Wenjun, Cao, Jing, Xiong, Fei, Wang, Yaru, Chai, Zemin, Cheng, Xiujun, Zhang, Yuan, Fu, Fanghui, Lang, Xiaoqiao, Wang, Xiaoling, Irwanto, Astrid, Krismawati, Hana, Fu, Xi’an, Sun, Yonghu, You, Jiabao, Liu, Jian, Pan, Qing, Chu, Tongsheng, Liu, Dianchang, Chen, Shumin, Shen, Jianping, Yan, Liangbin, Zhang, Guocheng, Liu, Jianjun, Zhang, Furen, Xiong, Li, Yang, Jun, Li, Jinlan, Ke, Wei, Li, Ming, Ning, Yong, Xiong, Junhao, Xiong, Mingzhou, Yang, Bin, Duan, Qizhi, Wang, Hong, Li, Wei, Kuang, Yanfei, Li, Junhua, Wang, Lamei, Cao, Qiuyang, Xiao, Peng, Xiao, Bangzhong, Zhang, Lianhua, Lin, Zhaoxing, Wang, Yaofei, Shen, Yunliang, Yan, Liying, Wu, Wenbin, Zheng, Hu, Zhan, Xianfa, Li, Wanghua, Shang, Xiujian, Xu, Yujun, and Liu, Qiao

Subjects
medicine.medical_specialty, business.industry, Standard treatment, Incidence (epidemiology), Dermatology, Dapsone, medicine.disease, Clofazimine, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Leprosy, Prospective cohort study, Adverse effect, business, Rifampicin, Original Investigation, medicine.drug
Abstract

IMPORTANCE: Dapsone hypersensitivity syndrome (DHS) is the most serious adverse reaction associated with dapsone administration and one of the major causes of death in patients with leprosy, whose standard treatment includes multidrug therapy (MDT) with dapsone, rifampicin, and clofazimine. Although the HLA-B*13:01 polymorphism has been identified as the genetic determinant of DHS in the Chinese population, no studies to date have been done to evaluate whether prospective HLA-B*13:01 screening could prevent DHS by identifying patients who should not receive dapsone. OBJECTIVE: To evaluate the clinical use of prospective HLA-B*13:01 screening for reduction of the incidence of DHS by excluding dapsone from the treatment for patients with HLA-B*13:01–positive leprosy. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study was conducted from February 15, 2015, to April 30, 2018, in 21 provinces throughout China. A total of 1539 patients with newly diagnosed leprosy were enrolled who had not received dapsone previously. After excluding patients who had a history of allergy to sulfones or glucose-6-phosphate dehydrogenase deficiency, 1512 individuals underwent HLA-B*13:01 genotyping. All of the patients were followed up weekly for the first 8 weeks after treatment to monitor for adverse events. EXPOSURES: Patients who were HLA-B*13:01 carriers were instructed to eliminate dapsone from their treatment regimens, and noncarrier patients received standard MDT. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of DHS. The historical incidence rate of DHS (1.0%) was used as a control. RESULTS: Among 1512 patients (1026 [67.9%] men, 486 [32.1%] women; mean [SD] age, 43.1 [16.2] years), 261 (17.3%) were identified as carriers of the HLA-B*13:01 allele. A total of 714 adverse events in 384 patients were observed during the follow-up period. Dapsone hypersensitivity syndrome did not develop in any of the 1251 patients who were HLA-B*13:01–negative who received dapsone, while approximately 13 patients would be expected to experience DHS, based on the historical incidence rate of 1.0% per year (P = 2.05 × 10(−5)). No significant correlation was found between other adverse events, including dermatologic or other events, and HLA-B*13:01 status. CONCLUSIONS AND RELEVANCE: Prospective HLA-B*13:01 screening and subsequent elimination of dapsone from MDT for patients with HLA-B*13:01–positive leprosy may significantly reduce the incidence of DHS in the Chinese population.

Published
2019

19. Preliminary study of tetracycline resistance genes in Treponema pallidum

Author

Xiao, Hailu, primary, Li, Zhen, additional, Li, Furong, additional, Wen, Jing, additional, Liu, Danxuan, additional, Du, Wenli, additional, Hou, Jianling, additional, Li, Zhongwei, additional, Zheng, Rongtao, additional, Liu, Dianchang, additional, Chu, Tongsheng, additional, Du, Donghong, additional, and Tian, Hongqing, additional

Published
2017
Full Text
View/download PDF

21. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy

Author

Liu, Hong, Wang, Zhenzhen, Bao, Fangfang, Wang, Chuan, Sun, Lele, Zhang, Huimin, Yu, Gongqi, Mi, Zihao, Li, Jianke, Li, Lulu, Zhao, Qing, Yue, Zhenhua, Zhao, Wei, Yu, Wenjun, Cao, Jing, Xiong, Fei, Wang, Yaru, Chai, Zemin, Cheng, Xiujun, Zhang, Yuan, Fu, Fanghui, Lang, Xiaoqiao, Wang, Xiaoling, Irwanto, Astrid, Krismawati, Hana, Fu, Xi’an, Sun, Yonghu, You, Jiabao, Liu, Jian, Pan, Qing, Chu, Tongsheng, Liu, Dianchang, Chen, Shumin, Shen, Jianping, Yan, Liangbin, Zhang, Guocheng, Liu, Jianjun, Zhang, Furen, Xiong, Li, Yang, Jun, Li, Jinlan, Ke, Wei, Li, Ming, Ning, Yong, Xiong, Junhao, Li, Ming, Xiong, Mingzhou, Yang, Bin, Duan, Qizhi, Wang, Hong, Li, Wei, Kuang, Yanfei, Li, Junhua, Wang, Lamei, Cao, Qiuyang, Xiao, Peng, Xiao, Bangzhong, Zhang, Lianhua, Lin, Zhaoxing, Wang, Yaofei, Shen, Yunliang, Yan, Liying, Wu, Wenbin, Zheng, Hu, Zhan, Xianfa, Li, Wanghua, Shang, Xiujian, Xu, Yujun, and Liu, Qiao

Abstract

IMPORTANCE: Dapsone hypersensitivity syndrome (DHS) is the most serious adverse reaction associated with dapsone administration and one of the major causes of death in patients with leprosy, whose standard treatment includes multidrug therapy (MDT) with dapsone, rifampicin, and clofazimine. Although the HLA-B*13:01 polymorphism has been identified as the genetic determinant of DHS in the Chinese population, no studies to date have been done to evaluate whether prospective HLA-B*13:01 screening could prevent DHS by identifying patients who should not receive dapsone. OBJECTIVE: To evaluate the clinical use of prospective HLA-B*13:01 screening for reduction of the incidence of DHS by excluding dapsone from the treatment for patients with HLA-B*13:01–positive leprosy. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study was conducted from February 15, 2015, to April 30, 2018, in 21 provinces throughout China. A total of 1539 patients with newly diagnosed leprosy were enrolled who had not received dapsone previously. After excluding patients who had a history of allergy to sulfones or glucose-6-phosphate dehydrogenase deficiency, 1512 individuals underwent HLA-B*13:01 genotyping. All of the patients were followed up weekly for the first 8 weeks after treatment to monitor for adverse events. EXPOSURES: Patients who were HLA-B*13:01 carriers were instructed to eliminate dapsone from their treatment regimens, and noncarrier patients received standard MDT. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of DHS. The historical incidence rate of DHS (1.0%) was used as a control. RESULTS: Among 1512 patients (1026 [67.9%] men, 486 [32.1%] women; mean [SD] age, 43.1 [16.2] years), 261 (17.3%) were identified as carriers of the HLA-B*13:01 allele. A total of 714 adverse events in 384 patients were observed during the follow-up period. Dapsone hypersensitivity syndrome did not develop in any of the 1251 patients who were HLA-B*13:01–negative who received dapsone, while approximately 13 patients would be expected to experience DHS, based on the historical incidence rate of 1.0% per year (P = 2.05 × 10−5). No significant correlation was found between other adverse events, including dermatologic or other events, and HLA-B*13:01 status. CONCLUSIONS AND RELEVANCE: Prospective HLA-B*13:01 screening and subsequent elimination of dapsone from MDT for patients with HLA-B*13:01–positive leprosy may significantly reduce the incidence of DHS in the Chinese population.

Published
2019
Full Text
View/download PDF

22. Discovery of six new susceptibility loci and analysis of pleiotropic effects in leprosy

Author

Liu, Hong, primary, Irwanto, Astrid, additional, Fu, Xi'an, additional, Yu, Gongqi, additional, Yu, Yongxiang, additional, Sun, Yonghu, additional, Wang, Chuan, additional, Wang, Zhenzhen, additional, Okada, Yukinori, additional, Low, Huiqi, additional, Li, Yi, additional, Liany, Herty, additional, Chen, Mingfei, additional, Bao, Fangfang, additional, Li, Jinghui, additional, You, Jiabao, additional, Zhang, Qilin, additional, Liu, Jian, additional, Chu, Tongsheng, additional, Andiappan, Anand Kumar, additional, Wang, Na, additional, Niu, Guiye, additional, Liu, Dianchang, additional, Yu, Xiulu, additional, Zhang, Lin, additional, Tian, Hongqing, additional, Zhou, Guizhi, additional, Rotzschke, Olaf, additional, Chen, Shumin, additional, Zhang, Xuejun, additional, Liu, Jianjun, additional, and Zhang, Furen, additional

Published
2015
Full Text
View/download PDF

23. Disparity in Availability of Laboratory Testing for Syphilis Among Different Hospitals in Shandong Province, Eastern China.

Author

Chen X, Mi X, Gan Y, Chang D, and Liu D

Subjects
China epidemiology, Hospitals, Humans, Syphilis Serodiagnosis, Syphilis diagnosis, Syphilis epidemiology
Abstract

The aim of this study was to understand the availability of laboratory testing for syphilis among hospitals in Shandong province. Basic information on hospitals that provide clinical health service for sexually transmitted infections (STIs) and the type of laboratory tests for syphilis provided was collected and analyzed using the chi-square test. A total of 410 and 456 hospitals that provided clinical services for STI were surveyed in 2012 and 2018. Significant differences in the availability of nontreponemal tests were observed among different levels (χ 2 = 6.624) and types (χ 2 = 17.752) of hospitals in 2012, but not in 2018. A significant difference in the availability of treponemal tests was observed among different levels of hospitals in 2012 (χ 2 = 9.937) but not in 2018. Significant differences in the availability of nontreponemal tests, titer of nontreponemal tests, and treponemal tests were observed among hospitals with different affiliations in 2018 ( P = 0.000; χ 2 = 15.274, P < .001; P = .021) but not in 2012. The availability of nontreponemal and treponemal tests for syphilis among hospitals in 2018 was higher than that in 2012 (90.13% vs. 57.56%, χ 2 = 121.219). The availability of laboratory testing has been much improved. Further efforts are needed to reduce the disparity in the availability among different hospitals.

Published
2022
Full Text
View/download PDF

24. Comparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis.

Author

Xiao H, Liu D, Li Z, Zheng R, Li Z, Hou J, Zhang S, Chu T, Tian H, and Zhang F

Subjects
Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Anti-Bacterial Agents therapeutic use, Doxycycline therapeutic use, Penicillin G Benzathine therapeutic use, Syphilis drug therapy
Abstract

Doxycycline is the preferred recommended second-line treatment for the treatment of early syphilis. Recent reports showed a declining efficacy trend of doxycycline in treatment of early syphilis. The aim of our study was to assess the serological response to the treatment for early syphilis with doxycycline compared with benzathine penicillin G and evaluate whether doxycycline is still an effective agent for the treatment of early syphilis. A record-based retrospective study was conducted. Patients were diagnosed with early syphilis in an sexually transmitted disease (STD) clinic from January 1, 2008 to December 31, 2014. They were treated with a single dose of benzathine penicillin G 2.4MU or oral doxycycline 100 mg twice daily for 14 days. Pearson's chi-squared test was used for data analysis. 601 cases were included in the final study sample: 105 (17.5%) patients received a 14-day course of doxycycline (doxycycline group), and 496 (82.5%) patients received single-dose benzathine penicillin G (BPG group). The serological responses at 6 months and 12 months after treatment were compared. No statistically significant differences were found between the two groups at 6 months (69.52% vs. 75.00%, P=0.245), and at 12 months (92.38% vs. 96.17%, P=0.115). Doxycycline is still an effective agent for the treatment of early syphilis.

Published
2017

25. TRENDS IN THE PREVALENCE OF SYPHILIS AMONG OLDER ADULTS IN SHANDONG, CHINA.

Author

Liu D, Yang Y, Xiu C, Li Z, Chu T, and Tian H

Subjects
Age Distribution, Aged, Aged, 80 and over, China epidemiology, Female, Humans, Male, Middle Aged, Population Surveillance, Prevalence, Retrospective Studies, Sex Distribution, Syphilis epidemiology
Abstract

The epidemiology of syphilis among older adults in China has not been well studied. We studied changes over time in the prevalence of syphilis among older adults in Shandong, China to inform a syphilis intervention program in order to develop management strategies. We retrospectively reviewed passive surveillance data of syphilis among older adults in Shandong, China during 2008-2013, reported by clinicians in medical facilities. The data included the stage of syphilis, age of patient and gender by year. The prevalences for first, second, latent and overall syphilis by age among adults aged ≥60 years in Shandong were 0.92, 0.70, 2.37 and 3.92 cases per 100,000 population in 2008 and 2.66, 1.99, 9.11 and 13.95 cases per 100,000 population in 2013; giving average yearly increases of 23.66%, 23.24%, 30.90% and 28.90%, respectively. The reported overall prevalence of syphilis among those aged ≥80 years was greater than the general population (8.25 vs 4.38 cases per 100,000 population in 2008; 21.99 vs 13.95 cases per 100,000 population in 2013). The prevalence of syphilis is increasing in the study population. Age appropriate interventions are needed to reduce the prevalence of syphilis in the study population.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results